Israele - inglese - Ministry of Health

abic marketing ltd, israel - methotrexate - solution for injection - methotrexate 25 mg/ml - methotrexate - methotrexate - antineoplastic chemotherapy: treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. palliation of acute lymphocytic leukemia. abitrexate is also indicated in the treatment and prophylaxis of meningeal leukemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. in combination with other anticancer agents, abitrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. abitrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. abitrexate is effective in the treatment of the advanced stages (iii and iv peter's staging system) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides. psoriasis: because of the high risk attending its use, abitrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: abitrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

brown & burk uk ltd - acrivastine - oral capsule - 8mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - acrivastine - oral capsule - 8mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - acrivastine - oral capsule - 8mg

Giappone - inglese - すりの適正使用協議会 RAD-AR Council, Japan

towa pharmaceutical co., ltd. - trimebutine maleate - white to pale yellowish white tablet, diameter 8.1 mm, thickness 3.4 mm

Australia - inglese - APVMA (Australian Pesticides and Veterinary Medicines Authority)

azelis australia pty limited - tin present as tri-n-butyltin naphthenate; permethrin (25:75::cis:trans); liquid hydrocarbon - liquid concentrate - tin present as tri-n-butyltin naphthenate organotin active 180.0 g/l; permethrin (25:75::cis:trans) pyrethroid active 45.0 g/l; liquid hydrocarbon solvent other 160.0 g/l - insecticide - timber-use inside/above ground-ref label | timber - hazard level(h1) | timber - hazard level(h2) | timber - hazard level(h3) | t - auger beetle | brown rot fungus | fungal decay | furniture beetle | pinhole borer | powderpost beetle | soft rot | subterranean termite - coptotermes spp. | subterranean termite - schedorhinotermes | subterranean termite incl. m.darwiniensi | termite | termite - mastotermes spp. | white rot fungus | coptotermes spp. | decay fungi | drywood termite | giant northern termite | mastotermes darwiniensis | platypodiae | schedorhinotermes spp. | subterranean termite

Australia - inglese - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - venetoclax, quantity: 50 mg - tablet, film coated - excipient ingredients: sodium stearylfumarate; copovidone; polysorbate 80; colloidal anhydrous silica; calcium hydrogen phosphate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; ferrosoferric oxide - acute myeloid leukaemia,venclexta, as part of combination therapy, is indicated for the treatment of newly diagnosed adult patients with acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.,this medicine has provisional approval in australia for the treatment of newly diagnosed patients with aml who are ineligible for intensive chemotherapy. the decision to approve this indication has been made on the basis of interim data (overall response rate and duration of response). continued approval of this indication depends on verification and description of benefit in confirmatory trials. chronic lymphocytic leukaemia/small lymphocytic lymphoma,venclexta in combination with obinutuzumab is indicated for the treatment of patients with chronic lymphocytic leukaemia (cll) or small lymphocytic lymphoma (sll) who are considered unfit or unsuitable for chemo-immunotherapy.,venclexta in combination with rituximab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.,venclexta monotherapy is indicated for the treatment of:,? patients with relapsed or refractory cll with 17p deletion, or,? patients with relapsed or refractory cll for whom there are no other suitable treatment options.,acute myeloid leukaemia,venclexta, in combination with azacitidine or low-dose cytarabine, is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Stati Uniti - inglese - NLM (National Library of Medicine)

natural health supply - tin (unii: 387gmg9fh5) (tin - unii:387gmg9fh5) - indications: to be used for acute self-limiting conditions according to standard homeopathic indications purpose: hoarse cough

Stati Uniti - inglese - NLM (National Library of Medicine)

boiron - tin (unii: 387gmg9fh5) (tin - unii:387gmg9fh5) - wet cough* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

Stati Uniti - inglese - NLM (National Library of Medicine)

boiron - tin (unii: 387gmg9fh5) (tin - unii:387gmg9fh5) - wet cough* stop use and ask a doctor if symptoms persist for more than 3 days or worsen